Introduction
There have been changes to some recommendations in this guideline since publication.
This web version contains the current wording of the recommendations. For information about the changes see the web summary page for the guideline.
Diabetes is a disorder of carbohydrate metabolism that requires immediate changes in lifestyle.
In its chronic forms, diabetes is associated with long-term vascular complications, including retinopathy, nephropathy, neuropathy and vascular disease. Approximately 650,000 women give birth in England and Wales each year, and 2-5% of pregnancies involve women with diabetes.
Approximately 87.5% of pregnancies complicated by diabetes are estimated to be due to gestational diabetes (which may or may not resolve after pregnancy), with 7.5% being due to type 1 diabetes and the remaining 5% being due to type 2 diabetes. The prevalence of type 1 and type 2 diabetes is increasing. In particular, type 2 diabetes is increasing in certain minority ethnic groups (including people of African, black Caribbean, South Asian, Middle Eastern and Chinese family origin).
Diabetes in pregnancy is associated with risks to the woman and to the developing fetus.
Miscarriage, pre-eclampsia and preterm labour are more common in women with pre-existing diabetes. In addition, diabetic retinopathy can worsen rapidly during pregnancy. Stillbirth, congenital malformations, macrosomia, birth injury, perinatal mortality and postnatal adaptation problems (such as hypoglycaemia) are more common in babies born to women with pre-existing diabetes.
This clinical guideline contains recommendations for the management of diabetes and its complications in women who wish to conceive and those who are already pregnant. The guideline builds on existing clinical guidelines for routine care during the antenatal, intrapartum and postnatal periods. It focuses on areas where additional or different care should be offered to women with diabetes and their newborn babies.
Where the evidence supports it, the guideline makes separate recommendations for women with pre-existing diabetes (type 1 diabetes, type 2 diabetes and other forms of diabetes, such as maturity onset diabetes of the young) and gestational diabetes. The term 'women' is used in the guideline to refer to all females of childbearing age, including young women who have not yet transferred from paediatric to adult services.
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The guideline will assume that prescribers will use a drug's summary of product characteristics (SPC) to inform their decisions for individual women.

Woman-and baby-centred care
This guideline offers best practice advice on the care of women with diabetes who are planning to become pregnant, or who are already pregnant, and their newborn babies.
Treatment and care should take into account women's needs and preferences. Women with diabetes should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If women do not have the capacity to make decisions, healthcare professionals should follow the Department of Health's advice on consent and the code of practice that accompanies the Mental Capacity Act. In Wales, healthcare professionals should follow advice on consent from the Welsh Government.
Good communication between healthcare professionals and women is essential. It should be supported by evidence-based written information tailored to the woman's needs. Treatment and care, and the information women are given about it, should be culturally appropriate. It should also be accessible to women with additional needs such as physical, sensory or learning disabilities, and to women who do not speak or read English.
Care of young women in transition between paediatric and adult services should be planned and managed according to the best practice guidance described in 'Transition: getting it right for young people'. Adult and paediatric healthcare teams should work jointly to provide care for young women with diabetes.
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Key priorities for implementation
Pre-conception care
Women with diabetes who are planning to become pregnant should be informed that establishing good glycaemic control before conception and continuing this throughout pregnancy will reduce the risk of miscarriage, congenital malformation, stillbirth and neonatal death. It is important to explain that risks can be reduced but not eliminated.
The importance of avoiding unplanned pregnancy should be an essential component of diabetes education from adolescence for women with diabetes.
Women with diabetes who are planning to become pregnant should be offered preconception care and advice before discontinuing contraception.
Antenatal care
If it is safely achievable, women with diabetes should aim to keep fasting blood glucose between 3.5 and 5.9 mmol/litre and 1-hour postprandial blood glucose below 7.8 mmol/litre during pregnancy.
Women with insulin-treated diabetes should be advised of the risks of hypoglycaemia and hypoglycaemia unawareness in pregnancy, particularly in the first trimester.
During pregnancy, women who are suspected of having diabetic ketoacidosis should be admitted immediately for level 2 critical care [1] , where they can receive both medical and obstetric care.
Women with diabetes should be offered antenatal examination of the four-chamber view of the fetal heart and outflow tracts at 18-20 weeks.
Neonatal care
Babies of women with diabetes should be kept with their mothers unless there is a clinical complication or there are abnormal clinical signs that warrant admission for intensive or special care.
Postnatal care
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Women who were diagnosed with gestational diabetes should be offered lifestyle advice (including weight control, diet and exercise) and offered a fasting plasma glucose measurement (but not an oral glucose tolerance test) at the 6-week postnatal check and annually thereafter.
[1] Level 2 critical care is defined as care for patients requiring detailed observation or intervention, including support for a single failing organ system or postoperative care and those 'stepping down' from higher levels of care.
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Guidance
The following guidance is based on the best available evidence. The full guideline gives details of the methods and the evidence used to develop the guidance.
In this reissued guidance, the information on the therapeutic indications, contraindications and use in pregnancy and lactation of drugs used in diabetes management and retinal assessment (specifically insulins, the oral hypoglycaemic agents metformin and glibenclamide, and tropicamide) has been corrected to follow the relevant SPCs (July 2008). Changes have been made to the introduction, to recommendation 1.1.6.2 and to the footnotes of recommendations 1.1.6.1, 1.2.2.12 and 1.6.1.4. Footnotes have been deleted from recommendations 1.1.6.2, 1.1.6.3, 1.1.10.2, 1.3.3.1 and 1.3.4.1.
Pre-conception care
Outcomes and risks for the woman and baby
1.1.1.1 Healthcare professionals should seek to empower women with diabetes to make the experience of pregnancy and childbirth a positive one by providing information, advice and support that will help to reduce the risks of adverse pregnancy outcomes for mother and baby.
1.1.1.2 Women with diabetes who are planning to become pregnant should be informed that establishing good glycaemic control before conception and continuing this throughout pregnancy will reduce the risk of miscarriage, congenital malformation, stillbirth and neonatal death. It is important to explain that risks can be reduced but not eliminated. the increased risk of having a baby who is large for gestational age, which increases the likelihood of birth trauma, induction of labour and caesarean section the need for assessment of diabetic retinopathy before and during pregnancy the need for assessment of diabetic nephropathy before pregnancy the importance of maternal glycaemic control during labour and birth and early feeding of the baby in order to reduce the risk of neonatal hypoglycaemia the possibility of transient morbidity in the baby during the neonatal period, which may require admission to the neonatal unit the risk of the baby developing obesity and/or diabetes in later life. 1.1.6 The safety of medications for diabetes before and during pregnancy 1.1.6.1 Women with diabetes may be advised to use metformin [3] as an adjunct or alternative to insulin in the pre-conception period and during pregnancy, when the likely benefits from improved glycaemic control outweigh the potential for harm. All other oral hypoglycaemic agents should be discontinued before pregnancy and insulin substituted.
The importance of planning pregnancy and the role of contraception
1.1.6.2 Healthcare professionals should be aware that data from clinical trials and other sources do not suggest that the rapid-acting insulin analogues (aspart and lispro) adversely affect the pregnancy or the health of the fetus or newborn baby.
1.1.6.3 Women with insulin-treated diabetes who are planning to become pregnant should be informed that there is insufficient evidence about the use of longacting insulin analogues during pregnancy. Therefore isophane insulin (also known as NPH insulin) remains the first choice for long-acting insulin during pregnancy. 1.1.9 Self-management programmes 1.1.9.1 Women with diabetes who are planning to become pregnant should be offered a structured education programme as soon as possible if they have not already attended one (see 'Guidance on the use of patient-education models for diabetes', NICE technology appraisal guidance 60 [4] ).
The safety of medications for diabetic complications before and during pregnancy
1.1.9.2 Women with diabetes who are planning to become pregnant should be offered pre-conception care and advice before discontinuing contraception. [3] and glibenclamide [6] ]) should be tailored to the glycaemic profile of, and acceptability to, the individual woman. 
Retinal assessment in the pre-conception period
Antenatal care
Intrapartum care
This section should be read in conjunction with 'Intrapartum care: care of healthy women and their babies during childbirth' (NICE clinical guideline 55). This guideline includes information on timing and mode of birth for uncomplicated births at term. jaundice requiring intense phototherapy and frequent monitoring of bilirubinaemia been born before 34 weeks (or between 34 and 36 weeks if dictated clinically by the initial assessment of the baby and feeding on the labour ward).
Timing and mode of birth
1.5.1.6 Babies of women with diabetes should not be transferred to community care until they are at least 24 hours old, and not before healthcare professionals are satisfied that the babies are maintaining blood glucose levels and are feeding well. 
Prevention and assessment of neonatal hypoglycaemia
Postnatal care
This section should be read in conjunction with 'Postnatal care: routine postnatal care of women and their babies' (NICE clinical guideline 37). This guideline includes information on the care that all women and babies should receive in the first 6-8 weeks after birth (including information about breastfeeding).
Breastfeeding and effects on glycaemic control
1.6.1.1 Women with insulin-treated pre-existing diabetes should reduce their insulin immediately after birth and monitor their blood glucose levels carefully to establish the appropriate dose.
1.6.1.2 Women with insulin-treated pre-existing diabetes should be informed that they are at increased risk of hypoglycaemia in the postnatal period, especially when breastfeeding, and they should be advised to have a meal or snack available before or during feeds.
1.6.1.3 Women who have been diagnosed with gestational diabetes should discontinue hypoglycaemic treatment immediately after birth.
1.6.1.4 Women with pre-existing type 2 diabetes who are breastfeeding can resume or continue to take metformin [3] and glibenclamide [6] immediately following birth but other oral hypoglycaemic agents should be avoided while breastfeeding.
1.6.1.5 Women with diabetes who are breastfeeding should continue to avoid any drugs for the treatment of diabetes complications that were discontinued for safety reasons in the pre-conception period. [3] Metformin is used in UK clinical practice in the management of diabetes in pregnancy and lactation. There is strong evidence for its effectiveness and safety, which is presented in the full Diabetes in pregnancy NICE clinical guideline 63 version of the guideline. This evidence is not currently reflected in the SPC (July 2008). The SPC advises that when a patient plans to become pregnant and during pregnancy, diabetes should not be treated with metformin but insulin should be used to maintain blood glucose levels. Informed consent on the use of metformin in these situations should be obtained and documented.
[4] 'Type 2 diabetes: the management of type 2 diabetes' (NICE clinical guideline 66) updates the information on type 2 diabetes in this technology appraisal. [6] Glibenclamide is used in UK clinical practice in the management of diabetes in pregnancy and lactation. There is strong evidence for its effectiveness and safety, which is presented in the full version of the guideline. This evidence is not currently reflected in the SPC (July 2008). The SPC advises that there is insufficient/limited information on the excretion of glibenclamide in human or animal breast milk. Informed consent on the use of glibenclamide during lactation should be obtained and documented.
[7] For the purpose of this guidance, 'disabling hypoglycaemia' means the repeated and unpredicted occurrence of hypoglycaemia requiring third-party assistance that results in continuing anxiety about recurrence and is associated with significant adverse effect on quality of life.
[8] Level 2 critical care is defined as care for patients requiring detailed observation or intervention, including support for a single failing organ system or postoperative care and those 'stepping down' from higher levels of care. 
Research recommendations
The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and the care of women with diabetes and their newborn babies in the future. The Guideline Development Group's full set of research recommendations is detailed in the full guideline (see section 5).
Screening, diagnosis and treatment for gestational diabetes
What is the clinical and cost effectiveness of the three main available screening techniques for gestational diabetes: risk factors, two-stage screening by the glucose challenge test and OGTT, and universal OGTT (with or without fasting)?
Why this is important
Following the Australian carbohydrate intolerance study in pregnant women (ACHOIS) it seems that systematic screening for gestational diabetes may be beneficial to the UK population. A multicentre randomised controlled trial is required to test the existing screening techniques, which have not been systematically evaluated for clinical and cost effectiveness (including acceptability) within the UK.
Monitoring blood glucose and ketones during pregnancy
How effective is ambulatory continuous blood glucose monitoring in pregnancies complicated by diabetes?
Why this is important
The technology for performing ambulatory continuous blood glucose monitoring is only just becoming available, so there is currently no evidence to assess its effectiveness outside the laboratory situation. Research is needed to determine whether the technology is likely to have a place in the clinical management of diabetes in pregnancy. The new technology may identify women in whom short-term postprandial peaks of glycaemia are not detected by intermittent Diabetes in pregnancy NICE clinical guideline 63 blood glucose testing. The aim of monitoring is to adjust insulin regimens to reduce the incidence of adverse outcomes of pregnancy (for example, fetal macrosomia, caesarean section and neonatal hypoglycaemia), so these outcomes should be assessed as part of the research.
Management of diabetes during pregnancy
Do new-generation CSII pumps offer an advantage over traditional intermittent insulin injections in terms of pregnancy outcomes in women with type 1 diabetes?
Why this is important
Randomised controlled trials have shown no advantage or disadvantage of using CSII pumps over intermittent insulin injections in pregnancy. A new generation of CSII pumps may offer technological advantages that would make a randomised controlled trial appropriate, particularly with the availability of insulin analogues (which may have improved the effectiveness of intermittent insulin injections).
Monitoring fetal growth and well-being
How can the fetus at risk of intrauterine death be identified in women with diabetes?
Why this is important
Unheralded intrauterine death remains a significant contributor to perinatal mortality in pregnancies complicated by diabetes. Conventional tests of fetal well-being (umbilical artery Doppler ultrasound, cardiotocography and other biophysical tests) have been shown to have poor sensitivity for predicting such events. Alternative approaches that include measurements of liquor erythropoietin and magnetic resonance imaging spectroscopy may be effective, but there is currently insufficient clinical evidence to evaluate them. Well-designed randomised controlled trials that are sufficiently powered are needed to determine whether these approaches are clinically and cost effective.
Glycaemic control during labour and birth
What is the optimal method for controlling glycaemia during labour and birth?
Why this is important
Epidemiological studies have shown that poor glycaemic control during labour and birth is associated with adverse neonatal outcomes (in particular, neonatal hypoglycaemia and respiratory distress). However, no randomised controlled trials have compared the effectiveness of intermittent subcutaneous insulin injections and/or CSII with that of intravenous dextrose plus insulin during labour and birth. The potential benefits of intermittent insulin injections and/or CSII over intravenous dextrose plus insulin during the intrapartum period include patient preference due to the psychological effect of the woman feeling in control of her diabetes and having increased mobility. Randomised controlled trials are therefore needed to evaluate the safety of intermittent insulin injections and/or CSII during labour and birth compared with that of intravenous dextrose plus insulin.
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Full guideline
The full guideline, 'Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period', contains details of the methods and evidence used to develop the guideline. It is published by the National Collaborating Centre for Women's and Children's Health.
Information for the public
Information for women with diabetes ('Information for the public') is available.
We encourage NHS and voluntary sector organisations to use text from this booklet in their own information about diabetes in pregnancy. 
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